Cindy Tahl is General Counsel and Secretary of FATE THERAPEUTICS INC. Currently has a direct ownership of 342,361 shares of FATE, which is worth approximately $575,166. The most recent transaction as insider was on Jul 29, 2024, when has been sold 200,000 shares (Common Stock) at a price of $0.0 per share, resulting in proceeds of $0. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 342K
0% 3M change
123.42% 12M change
Total Value Held $575,166

CINDY TAHL Transaction History

Date Transaction Value Shares Traded Shares Held Form
Jul 29 2024
BUY
Grant, award, or other acquisition
-
200,000 Added 36.88%
342,361 Common Stock
Jan 09 2024
SELL
Open market or private sale
$47,519 $4.37 p/Share
10,874 Reduced 7.1%
142,361 Common Stock
Nov 09 2023
SELL
Open market or private sale
$58,471 $2.4 p/Share
24,363 Reduced 13.72%
153,235 Common Stock
Jan 10 2023
SELL
Open market or private sale
$60,537 $5.24 p/Share
11,553 Reduced 6.11%
177,598 Common Stock
Jun 01 2022
SELL
Open market or private sale
$574,000 $22.96 p/Share
25,000 Reduced 11.67%
189,151 Common Stock
Jun 01 2022
BUY
Exercise of conversion of derivative security
$163,750 $6.55 p/Share
25,000 Added 10.45%
214,151 Common Stock
Apr 01 2022
SELL
Open market or private sale
$971,250 $38.85 p/Share
25,000 Reduced 11.67%
189,151 Common Stock
Apr 01 2022
BUY
Exercise of conversion of derivative security
$142,500 $5.7 p/Share
25,000 Added 10.45%
214,151 Common Stock
Jan 25 2022
BUY
Grant, award, or other acquisition
-
33,302 Added 14.97%
189,151 Common Stock
Jan 11 2022
SELL
Open market or private sale
$264,501 $48.81 p/Share
5,419 Reduced 3.36%
155,849 Common Stock
Jan 10 2022
SELL
Open market or private sale
$361,829 $46.76 p/Share
7,738 Reduced 4.58%
161,268 Common Stock
Jan 03 2022
SELL
Open market or private sale
$2,959,500 $59.19 p/Share
50,000 Reduced 22.83%
169,006 Common Stock
Jan 03 2022
BUY
Exercise of conversion of derivative security
$327,500 $6.55 p/Share
50,000 Added 18.59%
219,006 Common Stock
Nov 19 2021
BUY
Grant, award, or other acquisition
-
60,958 Added 26.51%
169,006 Common Stock
Oct 01 2021
SELL
Open market or private sale
$2,944,500 $58.89 p/Share
50,000 Reduced 31.64%
108,048 Common Stock
Oct 01 2021
BUY
Exercise of conversion of derivative security
$327,500 $6.55 p/Share
50,000 Added 24.03%
158,048 Common Stock
Jul 01 2021
SELL
Open market or private sale
$4,996,394 $89.97 p/Share
55,534 Reduced 33.95%
108,048 Common Stock
Jul 01 2021
BUY
Exercise of conversion of derivative security
$335,425 $6.04 p/Share
55,534 Added 25.34%
163,582 Common Stock
Apr 01 2021
SELL
Open market or private sale
$2,522,700 $84.09 p/Share
30,000 Reduced 21.73%
108,048 Common Stock
Apr 01 2021
BUY
Exercise of conversion of derivative security
$161,700 $5.39 p/Share
30,000 Added 17.85%
138,048 Common Stock
Jan 20 2021
BUY
Grant, award, or other acquisition
-
18,013 Added 14.29%
108,048 Common Stock
Jan 19 2021
SELL
Open market or private sale
$4,044,600 $115.56 p/Share
35,000 Reduced 27.99%
90,035 Common Stock
Jan 19 2021
BUY
Exercise of conversion of derivative security
$101,500 $2.9 p/Share
35,000 Added 21.87%
125,035 Common Stock
Jan 11 2021
SELL
Open market or private sale
$360,153 $110.68 p/Share
3,254 Reduced 3.49%
90,035 Common Stock
Jan 08 2021
SELL
Open market or private sale
$724,620 $116.33 p/Share
6,229 Reduced 6.26%
93,289 Common Stock
CT

Cindy Tahl

General Counsel and Secretary
San Diego, CA

Track Institutional and Insider Activities on FATE

Follow FATE THERAPEUTICS INC and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells FATE shares.

Notify only if

Insider Trading

Get notified when an Fate Therapeutics Inc insider buys or sells FATE shares.

Notify only if

News

Receive news related to FATE THERAPEUTICS INC

Track Activities on FATE